Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
等待开盘 11-07 09:30:00 美东时间
39.15
+0.010
+0.03%
华盛通- 最 高39.37
- 今 开38.85
- 成交量 8.72万股
- 最 低 38.52
- 昨 收 39.14
- 总市值 29.01亿
- 52周最高 42.05
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.82
- 委 比 -68.50%
- 总股本 7410.77万
- 历史最高 42.05
- 量 比 0.23
- 振 幅 2.17%
- 历史最低 5.01
- 每 手 1
- 风险率 6.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Kiniksa Expects 2025 Arcalyst Net Product Revenue Of $670M-$675M Compared To Prior Guidance Of $625M-$640M
Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
10-28 19:43
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
10-28 19:11
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong Q3 2025 results with ARCALYST net product revenue reaching $180.9 million, up 61% year-over-year, and raised its 2025 net product revenue guidance to $670-$675 million. KPL-387 received Orphan Drug Designation for pericarditis, and cash rose by $44.3 million to $352.1 million. The company plans a conference call to discuss these results.
10-28 11:30
What to Expect from Kiniksa Pharmaceuticals's Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly ear...
10-28 03:01
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
5 Analysts Have This To Say About Kiniksa Pharmaceuticals
In the preceding three months, 5 analysts have released ratings for Kiniksa Pha...
10-18 03:00
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Kiniksa Pharmaceuticals announced that the FDA granted Orphan Drug Designation to KPL-387 for treating pericarditis. KPL-387, a monoclonal antibody, inhibits IL-1α and IL-1β signaling. The company expects Phase 2/3 trial data in late 2026 and believes KPL-387 could offer a monthly subcutaneous self-injection treatment option. Orphan Drug Designation provides incentives for developing treatments for rare diseases.
10-17 12:00
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $38 to $44.
10-13 21:03
